Search Results - "KEYES, Mira"

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer by Rodda, Sree, MBBS, MRCP, FRCR, Tyldesley, Scott, MD, FRCPC, Morris, W. James, MD, FRCPC, Keyes, Mira, MD, FRCPC, Halperin, Ross, MD, FRCPC, Pai, Howard, MD, FRCPC, McKenzie, Michael, MD, FRCPC, Duncan, Graeme, MB, ChB, FRCPC, Morton, Gerard, MB, MRCPI, FRCPC, FFRRCSI, Hamm, Jeremy, MSC, Murray, Nevin, MD, FRCPC

“…Purpose To report the genitourinary (GU) and gastrointestinal (GI) morbidity and erectile dysfunction in a randomized trial comparing 2 methods of dose…”
Get full text

A biochemical definition of cure after brachytherapy for prostate cancer by Crook, Juanita M., Tang, Chad, Thames, Howard, Blanchard, Pierre, Sanders, Jeremiah, Ciezki, Jay, Keyes, Mira, Morris, W. James, Merrick, Gregory, Catton, Charles, Raziee, Hamid, Stock, Richard, Sullivan, Frank, Anscher, Mitch, Millar, Jeremy, Frank, Steven

“…•Close to 80% of men 4–5 years after LDR prostate brachytherapy will achieve a PSA of 0.2 ng/ml or less.•PSA ≤ 0.2 ng/ml is associated with 97–99% freedom from…”
Get full text

Information Needs of Patients Diagnosed with Head and Neck Cancer Undergoing Radiation Therapy: a Survey of Patient Satisfaction by Kim, Cecilia, Dillon, Ruth, Nica, Luminita, Berthelet, Eric, Keyes, Mira, Hamilton, Sarah Nicole

“…Research suggests that the information needs of patients diagnosed with head and neck cancer can be particularly complex, given the frequent need for…”
Get full text

Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer by Morris, W. James, Keyes, Mira, Spadinger, Ingrid, Kwan, Winkle, Liu, Mitchell, McKenzie, Michael, Pai, Howard, Pickles, Tom, Tyldesley, Scott

“…BACKGROUND. The objective of this study was to report the rates of disease‐free survival (DFS), cause‐specific survival (CSS), and overall survival after…”
Get full text

106 Degree of immune infiltration in active surveillance prostate patients detected by quantitative DNA staining helps predict progression by MacAulay, Calum, Guillaud, Martial, Keyes, Mira

“…BackgroundBiomarkers that can identify which active surveillance (AS) prostate patients are likely to progress would have clinical utility.MethodsUsing a DNA…”
Get full text

Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients by Keyes, Mira, M.D, Miller, Stacy, M.D, Moravan, Veronika, M.Sc, Pickles, Tom, M.D, McKenzie, Michael, M.D, Pai, Howard, M.D, Liu, Mitchell, M.D.C.M, Kwan, Winkle, M.D, Agranovich, Alexander, M.D, Spadinger, Ingrid, Ph.D, Lapointe, Vincent, M.Sc, Halperin, Ross, M.D, Morris, W. James, M.D

“…Purpose To describe the frequency of acute and late Radiation Therapy Oncology Group (RTOG) urinary toxicity, associated predictive factors, and resolution of…”
Get full text

Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival by Lo, Andrea C., MD, Morris, W. James, MD, FRCPC, Lapointe, Vincent, BSc, Hamm, Jeremy, MSc, Keyes, Mira, MD, FRCPC, Pickles, Tom, MD, FRCPC, McKenzie, Michael, MD, FRCPC, Spadinger, Ingrid, PhD

“…Purpose To determine ( 1 ) the prognostic utility of prostate-specific antigen (PSA) concentration at 45 to 60 months (48mPSA) after low-dose-rate prostate…”
Get full text

Brachytherapy or Conformal External Radiotherapy for Prostate Cancer: A Single-Institution Matched-Pair Analysis by Pickles, Tom, M.D, Keyes, Mira, M.D, Morris, W. James, M.D

“…Purpose In the absence of randomized study data, institutional case series have shown brachytherapy (BT) to produce excellent biochemical control (bNED) in…”
Get full text

Clinical and pathological characteristics of bladder cancer in post brachytherapy patients by Au, Sammy, Keyes, Mira, Black, Peter, Villamil, Carlos F., Tavassoli, Peyman

“…The long-term risk of secondary malignancy is a potential late effect of brachytherapy. However, the time interval, anatomic site and histopathology are not…”
Get full text

Late Urinary Side Effects 10 Years After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric Goals by Keyes, Mira, MD, Miller, Stacy, MD, Pickles, Tom, MD, Halperin, Ross, MD, Kwan, Winkle, MD, Lapointe, Vincent, BSc, McKenzie, Michael, MD, Spadinger, Ingrid, PhD, Pai, Howard, MD, Chan, Elisa K., MD, Morris, W. James, MD

“…Purpose To determine late urinary toxicity (>12 months) in a large cohort of uniformly treated low-dose-rate prostate brachytherapy patients. Methods and…”
Get full text

Treatment options for localized prostate cancer by Keyes, Mira, Crook, Juanita, Morton, Gerard, Vigneault, Eric, Usmani, Nawaid, Morris, W James

“…To describe treatment options for clinically localized prostate cancer: radical prostatectomy, prostate brachytherapy, external beam radiation, and active…”
Get full text

Incidence of Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy by Hamilton, Sarah Nicole, MD, Tyldesley, Scott, MD, FRCPC, Hamm, Jeremy, MSc, Jiang, Wei Ning, BScN, Keyes, Mira, MD, FRCPC, Pickles, Tom, MD, FRCPC, Lapointe, Vince, BSc, Kahnamelli, Adam, BSc, McKenzie, Michael, MD, FRCPC, Miller, Stacy, MD, FRCPC, Morris, W. James, MD, FRCPC

“…Purpose To compare the second malignancy incidence in prostate cancer patients treated with brachytherapy (BT) relative to radical prostatectomy (RP) and to…”
Get full text

Should Women Younger Than 40 Years of Age With Invasive Breast Cancer Have a Mastectomy?: 15-Year Outcomes in a Population-Based Cohort by Cao, Jeffrey Q., MD, MBA, FRCPC, Truong, Pauline T., MD, FRCPC, Olivotto, Ivo A., MD, FRCPC, Olson, Robert, MD, FRCPC, MSc, Coulombe, Genevieve, MD, FRCPC, Keyes, Mira, MD, FRCPC, Weir, Lorna, MD, FRCPC, Gelmon, Karen, MD, FRCPC, Bernstein, Vanessa, MD, FRCPC, Woods, Ryan, MSc, Speers, Caroline, BA, Tyldesley, Scott, MD, FRCPC

“…Purpose Optimal local management for young women with early-stage breast cancer remains controversial. This study examined 15-year outcomes among women younger…”
Get full text

Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients by Lo, Andrea C., MD, Morris, W. James, MD, FRCPC, Pickles, Tom, MD, FRCPC, Keyes, Mira, MD, FRCPC, McKenzie, Michael, MD, FRCPC, Tyldesley, Scott, MD, FRCPC

“…Objectives This study examined patterns of recurrence after low–dose-rate prostate brachytherapy (LDR-PB), estimated local recurrence rate and compared that…”
Get full text

Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program by Thaker, Nikhil G., MD, Kudchadker, Rajat J., PhD, Swanson, David A., MD, Albert, Jeffrey M., MD, MPH, Mahmood, Usama, MD, Pugh, Thomas J., MD, Boehling, Nicholas S., MD, Bruno, Teresa L., CMD, Prestidge, Bradley R., MD, Crook, Juanita M., MD, Cox, Brett W., MD, Potters, Louis, MD, Moran, Brian J., MD, Keyes, Mira, MD, Kuban, Deborah A., MD, Frank, Steven J., MD

“…Purpose To design and implement a unique training program that uses a phantom-based simulator to teach the process of prostate brachytherapy (PB) quality…”
Get full text

Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence by Pukl, Miha, Keyes, Sarah, Keyes, Mira, Guillaud, Martial, Volavšek, Metka

“…PURPOSEProstate cancer (PCa) with biopsy-based grade group (GG) 1 or 2 characteristics has a favorable outcome, yet some cases still progress after radical…”
Get full text

Segmental Urethral Dosimetry and Urinary Toxicity in Patients With No Urinary Symptoms Before Permanent Prostate Brachytherapy by Thomas, Carys, M.B.B.S, Keyes, Mira, M.D., F.R.C.P.C, Liu, Mitchell, M.D.C.M, Moravan, Veronika, M.Sc

“…Purpose To determine whether segmental urethral dosimetry is predictive for the degree of urinary morbidity after prostate brachytherapy in patients with no…”
Get full text

Evaluation of Dosimetric Parameters and Disease Response After {sup 125}Iodine Transperineal Brachytherapy for Low- and Intermediate-Risk Prostate Cancer by Morris, W. James, Keyes, Mira M.D., Palma, David M.D., McKenzie, Michael, Spadinger, Ingrid, Agranovich, Alex, Pickles, Tom, Liu, Mitchell, Kwan, Winkle, Wu, Jonn, Lapointe, Vince, Berthelet, Eric, Pai, Howard, Harrison, Robert, Kwa, William, Bucci, Joe, Racz, Violet, Woods, Ryan

“…Purpose: To analyze dosimetric outcomes after permanent brachytherapy for men with low-risk and 'low-tier' intermediate-risk prostate cancer and explore the…”
Get full text

Using a Surgical PSA-Threshold (> 0.2 ng/mL) to Define Biochemical Failure in the ASCENDE-RT Phase 3 Trial by Morris, William J., MD FRCPC, Keyes, Mira, MD FRCPC, Pickles, Tom, MD FRCPC

Get full text

DNA Ploidy Measured on Archived Pretreatment Biopsy Material May Correlate With Prostate-Specific Antigen Recurrence After Prostate Brachytherapy by Keyes, Mira, MD, MacAulay, Calum, PhD, Hayes, Malcolm, M Med Path, Korbelik, Jagoda, Bsc, Morris, W. James, MD, Palcic, Branko, PhD

“…Purpose To explore whether DNA ploidy of prostate cancer cells determined from archived transrectal ultrasound-guided biopsy specimens correlates with…”
Get full text